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Introduction
Brain metastases occur frequently in patients with cancer 
and certain cancers such as lung cancer, breast cancer, 
melanoma, and renal cell carcinoma carry a higher risk. 
About 30% of cancer patients will develop brain metastases 
and the incidence is rising (1). The judicious selection of 
treatment for patients with brain metastases is crucial to 
maximize positive outcomes including improvement of 
survival and preservation of neurocognitive function and 
quality of life. In the recent years, significant progress 
has been made to optimize treatment outcomes for brain 
metastases. As patients survive longer with the use of very 
effective cytotoxic chemotherapy and targeted therapy, 
they are more likely to suffer the toxic effects of their brain 
metastasis treatments. The most recent trials in brain 
metastases focus on reduction of toxicities of RT for brain 
metastases while maintaining the overall survival. The 
scope of this review is to highlight the recent advances of 
radiation therapy (RT) management of brain metastases 
based on prospective data.
Further evidence of using SRS alone for brain 
metastases
Multiple phase III randomized controlled trials (RCTs) 
had already confirmed the important role of stereotactic 
radiosurgery (SRS) in the management of multiple brain 
metastases (2-5). In the past 3 years, we have had more high 
quality evidence supporting the use of SRS alone for brain 
metastases. In 2015, Sahgal and colleagues published an 
individual patient data meta-analysis of phase 3 trials of SRS 
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with or without whole brain radiation therapy (WBRT) for 
1–4 brain metastases (6). The study pooled individual data 
of 364 patients from three RCTs (2,3,5). While it was not 
surprising that the meta-analysis confirmed that single brain 
metastasis patients had better overall survival and lower 
distant brain failure, it was the first report showing that 
age was an important modifier on treatment outcome. For 
patients with age <50 years old, addition of WBRT to SRS 
actually resulted in detrimental effect on overall survival. 
Hazard ratios (HRs) for patients 35, 40, 45, and 50 years of 
age were 0.46 [95% confidence interval (CI) =0.24–0.90), 
0.52 (95% CI =0.29–0.92), 0.58 (95% CI =0.35–0.95), 
and 0.64 (95% CI =0.42–0.99], respectively (Figure 1). In 
younger patients <50 years old, omission of WBRT did not 
affect distant brain failure rate. The authors hypothesized 
that those patients were exposed to the adverse effects of 
WBRT without yielding a therapeutic gain with respect 
to distant brain relapse rates, which may explain the 
phenomenon.
In clinical practice, given the observation mentioned 
above, when we encounter young brain metastases patients 
who will continue receive active systemic anti-cancer 
treatments, strong consideration should be given for 
omission of WBRT.
In 2016, the 4th phase III RCT on SRS with or without 
WBRT by the Alliance for Clinical Trials in Oncology 
group (NCCTG N0574) was published (7). Patients with 
1–3 brain metastases were randomized to SRS and SRS plus 
WBRT. The primary endpoint used was cognitive function 
decline at three months. Cognitive function deteriorated 
more frequently in patients who received WBRT plus 
SRS compared with SRS alone, especially in the domains 
of immediate recall, memory, and verbal fluency. The 
finding was consistent with previous phase III RCT by 
M.D. Anderson Cancer Center (3). It has also corroborated 
the facts that intracranial disease control is improved with 
the inclusion of adjuvant WBRT (3-month failure rate 
24.7% vs. 6.3%) but there is no improvement in overall 
survival. Given the presence of robust level 1 evidence 
supporting the omission of WBRT in patients with 
1–4 metastases, SRS alone should be the preferred 
treatment option for patients with limited brain metastases. 
Compared to WBRT plus SRS, the potential advantages 
of SRS alone include better preservation of neurocognitive 
function, better quality of life, rapid delivery as a single out-
patient session, minimal recovery time, and minimal delay 
in the re-initiation of systemic treatments. Furthermore, 
there is no negative impact on overall survival. In 2014, 
the American Society for Radiation Oncology (ASTRO) 
Choosing Wisely® Campaign has issued a statement 
recommending against routinely adding adjuvant WBRT to 
SRS for limited brain metastases.
Technological advances in treatment delivery and 
planning also allows SRS to be given efficiently and safely to 
patients with more than 4 brain metastases. In 2014, a phase 
II clinical trial JLGK0901 (8) was published by Yamamoto 
and colleagues. It was an adequately-powered, prospective, 
non-inferiority observational cohort study which had 
recruited patients with newly diagnosed 1–10 brain 
metastases. The treatment given was SRS alone without 
WBRT. The limit for total intracranial disease burden was 
a total volume ≤15 mL and the largest brain metastasis had 
to be ≤10 mL or ≤3 cm in longest diameter. Among the 
enrolled patients, the mean of the total volume of brain 
metastases was approximately 3 mL. More than 85% of 
patients in this cohort had Karnofsky Performance Status 
(KPS) of 80 or above. RPA class 1 patients constituted about 
28% and class 2 patients about 70%.
The result of JLGK0901 showed that the overall survival 
of patients with 5-10 brain metastases was not inferior to 
that of 2–4 brain metastases, and the side effect profile was 
similar between the two groups. The results of this trial 
corroborated those of other studies that the total volume, 
but not an arbitrary number of brain metastases, was a more 
important predictive factor for prognosis (9,10). The main 
Figure 1 Treatment effects of SRS vs. SRS plus WBRT and 
the corresponding 95% confidence intervals on survival at 35 
to 80 years of age. Figure extracted from Sahgal et al. (6). SRS, 
stereotactic radiosurgery; WBRT, whole brain radiation therapy.
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limitation was that the study did not have follow-up data 
on MRI, MMSE, neurocognitive function or quality of life 
measures. Nevertheless the study challenged the traditional 
dogma (11,12) that SRS should only be offered to patients 
with no more than 3–4 brain metastases. It also guided 
the future direction of clinical trials to compare WBRT 
and SRS in 4 or more brain metastases. A phase III RCT 
comparing WBRT vs. SRS alone in 5–15 brain metastases 
will be performed in North America to confirm the findings 
of JLGK0901 (ClinicalTrials.gov NCT03075072).
Neurocognitive function preservation
In the past, the potential impact of RT on cognitive function 
was largely ignored due to the very poor overall survival of 
brain metastases patients (13,14). With the advancement 
of systemic targeted therapy, the outcomes of patients have 
significantly improved, particularly amongst those with 
good prognostic factors (15). The routine use of WBRT in 
patients has drawn much controversy due to its impact on 
neurocognitive function (16) and quality of life (17).
The most studied approach for neurocognitive function 
preservation is the omission of WBRT. The Alliance study 
(NCCTG N0574) (7) has provided important information 
on the delicate balance of neurocognitive function and 
intracranial disease control. In the study, the primary 
endpoint of the study was set low at one standard deviation 
(SD) change in neurocognitive function tests. So even for 
SRS alone arm, the neurocognitive deterioration was high 
at around 64% vs. 92% of WBRT plus SRS arm. If the 
threshold was set at 2-SD change, the rates would drop to 
1.6% vs. 10.6% (18).
If we consider the 2-SD change in neurocognitive 
function as clinically significant, is it justified to improve 
intracranial control by upfront WBRT while taking 
around 10% risk of neurocognitive function deterioration? 
It is important to consider treatment which maximizes 
intracranial control especially if the local health system 
cannot arrange for frequent surveillance MRI and prompt 
salvage treatment for relapse. From the MD Anderson 
RCT (3), the one-year CNS progression rate was 73% 
for SRS alone arm and 27% for SRS plus WBRT arm 
(P=0.0003). For the Alliance study (7), the six-month 
CNS progression rate of the two arms were 35% vs. 12% 
(P<0.001).
The importance of maximizing intracranial control 
was illustrated by the earlier RCT reported by Aoyama et 
al. (2,19). In this RCT, SRS alone arm actually had worse 
functional outcome compared with SRS plus WBRT 
(41% vs. 24% at 12 months), as measured by a relatively 
crude scale of mini-mental state examination (MMSE). It 
was postulated that this was related to the inferior overall 
intracranial control caused by distant CNS recurrence.
On the other hand, there is active research effort to 
reduce the neurocognitive impact of WBRT while keeping 
the higher intracranial control rate. One approach is to 
use pharmacological agents for neuroprotection. In 2013, 
Brown et al. reported the results of RTOG 0614 (20), which 
was a multi-center RCT testing the use of memantine, an 
N-methyl-D-aspartate (NMDA) receptor antagonist, for 
protection of neurocognitive function in patients treated 
with conventional WBRT.
The primary end-point of the study, decline in delayed 
recall in 24 weeks, was negative. This was possibly due 
to the low rate of analyzable patients at 24 weeks (149 
out of 508 patients) which decreased the power of the 
study. Among the secondary endpoints, the patients in the 
memantine arm had significantly longer time to cognitive 
decline (HR 0.78, P=0.01). The patients in the memantine 
arm also had higher executive function, processing speed 
and delayed recognition. Overall, memantine was very well 
tolerated with minimal toxicity. So adding memantine is one 
of the most practical solutions for neurocognitive function 
preservation if WBRT is considered necessary.
Another approach to preserve neurocognitive function 
is by dosimetric sparing of hippocampus with advanced 
RT planning technique. Hippocampus is a vital structure 
for memory and learning. It is particularly sensitive to 
ionizing radiation injury which suppresses neurogenesis of 
hippocampal neural stem cell (21) and causes neurocognitive 
deterioration after WBRT. Hippocampal-avoidance whole 
brain radiation therapy (HA-WBRT) was hence proposed 
to preserve neurocognitive function in patients with brain 
metastases.
So far, there was no randomized data supporting the use 
of HA-WBRT. The most important evidence was from 
RTOG-0933 (22), which was a phase 2 single arm study 
published in 2014 comparing the neurocognitive outcomes 
of patients undergoing HA-WBRT to those of a historical 
cohort. The primary endpoint was Hopkins Verbal 
Learning Test–Revised Delayed Recall (HVLT-R DR) at 
4 months. The technical requirement of HA-WBRT was 
carefully defined (23). Planning MRI brain with ≤1.5 mm 
slice thickness and fusion to planning CT with ≤2.5 mm 
slice thickness was required. Hippocampus contouring 
protocol was set for clinicians. Dose to hippocampi was set 
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at D100% ≤9 Gy in 10 fractions and maximum dose ≤16 Gy 
in 10 fractions. Central rapid plan review was conducted in 
real time to ensure the plan quality.
Among 113 patients received HA-WBRT, 42 patients 
were analyzable at 4 months. Mean relative decline in 
HVLT-R DR from baseline to 4 months was 7.0% (22) (95% 
CI, 4.7–18.7%), significantly lower in comparison with the 
historical control of ~30% (24) (P≤0.001). No decline in 
QOL scores was observed. The results compared favorably 
against similar patient group in the M.D. Anderson 
group RCT (3). Another prospective study at Taiwan 
reproduced the finding of RTOG 0933. Forty patients were 
recruited and 24 of them were available for post-treatment 
assessment. Dosimetry parameters of hippocampus were 
correlated to the verbal memory scores of neurocognitive 
function (25).
The early encouraging results of the HA-WBRT 
demonstrated that it was technically feasible in clinical 
practice. However, further implementation in daily practice 
necessitates evidence from prospective randomized studies. 
Cost-effectiveness analysis is certainly important and will 
probably be determining if this technically demanding 
treatment will be adopted in the era of value-based 
medicine. Further studies on reproducible and less complex 
planning technique with lateral opposing beams and central 
leaf shielding (26) will help resources tight communities to 
practise HA-WBRT. Currently the NRG group (National 
Surgical Adjuvant Breast and Bowel Project, Radiation 
Therapy Oncology Group, and Gynecologic Oncology 
Group) is conducting the phase 3 CC-001 trial which is 
recruiting participants to compare Memantine and WBRT 
with or without hippocampal avoidance in reducing 
neurocognitive decline in patients with brain metastases 
(clinicaltrials.gov NCT02360215). 
Multidisciplinary approach for brain metastases
The conventional treatment after surgical removal of brain 
metastasis was WBRT. Although WBRT after surgical 
resection has been proven to decrease local failure rate, 
WBRT failed to improved overall survival (5,27). Due 
to the lack of overall survival benefit and the concern of 
neurocognitive function deterioration after WBRT, there 
has been a trend to treat the surgical cavity with SRS. But in 
retrospective studies the local control rate of surgical cavity 
was highly variable from 30–100% (28,29).
In 2016, three prospective phase 3 randomized studies 
on surgical cavity SRS were reported in abstract form. 
The N107C/CEC.3 (30) was a multicenter RCT which 
recruited 194 patients with 1–4 brain metastases. Patients 
were randomized to SRS to both the cavity and unresected 
metastases or WBRT plus SRS to unresected metastases 
after resection of one lesion. The M.D. Anderson Cancer 
Center trial by Mahajan et al. (31) included 131 patients 
with 1–3 brain metastases and had at least 1 brain metastases 
completely removed. Subjects were then randomized to 
SRS to the surgical cavity (or cavities) vs. observation. 
JCOG0504 (32) was a multi-institutional study from 
Japan. It recruited 271 patients with ≤4 brain met and one 
lesion >3 cm having been surgically resected. Patients were 
randomized to observation or salvage SRS for residual and 
recurrent tumors. The interventions and main results of the 
three RCTs were summarized in Table 1.
In summary, the three RCTs (30-32) confirmed the safety 
and efficacy of SRS to surgical cavity. The results were also 
consistent with the non-surgical RCTs that quality of life and 
cognitive functions were better preserved in SRS arm (30). 
However, caution has to be exercised for large lesion with 
pre-operative diameter >3 cm and superficial lesion with 
meningeal/pial involvement due to higher risk of local 
failure (31,33).
New evidence on the use of WBRT alone
WBRT has long been used for palliative treatment since 
it was first described in 1950s (34). Efficacy of WBRT in 
palliation of neurological signs and symptoms was reported 
in early clinical trials in 1980s (13,14). In resources limited 
health care systems, it is still the mainstay of treatment of 
brain metastases (35). However, despite its wide-spread 
use, the efficacy of WBRT alone for brain metastases in 
the modern era of effective systemic treatment was still 
uncertain until the latest publication of QUARTZ study (36) 
results.
The QUARTZ (quality of life after treatment for brain 
metastases) study was a non-inferiority, phase 3 study 
performed in UK and Australian centers. Non-small cell 
lung cancer patients (n=538) who were unsuitable for 
operative intervention or SRS were randomized to the 
optimal supportive care (OSC) arm with dexamethasone or 
the WBRT arm. The overall survival, overall quality of life 
and use of dexamethasone were not significantly different 
between two arms. The median overall survival times of 
both arms were around 9 weeks. The quality adjusted life 
year (QALY) was 46.4 and 41.7 days in WBRT arm and 
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OSC arm, respectively. Serious adverse event rates were 
similar in both arms, but patients in the WBRT arm had 
more drowsiness, hair loss, nausea, and dry or itchy scalp.
This study suggested that on average WBRT did not 
improve overall survival, quality of life or dexamethasone 
use in poor prognostic group lung cancer patients with 
brain metastases. Yet, there may be subgroups in this 
heterogeneous population that WBRT may offer advantage 
in overall survival. Younger patients, particularly those 
younger than 60 years old, had improved survival with 
WBRT. There was also non-significant association of 
overall survival with satisfactory KPS, controlled primary 
tumor status, good prognostic grouping by recursive 
partitioning analysis (RPA) (37) and graded prognostic 
assessment (GPA) (15). 
The role of RT in epidermal growth factor 
receptor (EGFR) mutated lung cancer patients 
with brain metastases
The application of QUARTZ data in Asia population is 
much affected by the high prevalence of EGFR activating 
mutation in the lung cancer patient populations (38). The 
survival pattern of EGFR mutated lung cancer patients with 
brain metastasis is so different that the Diagnosis-Specific 
Graded Prognostic Assessment (DS-GPA) was updated 
based on molecular markers (39). The updated DS-GPA, 
now known as the Lung-molGPA scores, included EGFR 
and ALK alterations in adenocarcinoma as predictors. The 
highest GPA score group of 3.5 to 4.0 had a median survival 
of nearly 4 years.
There was an argument in favor of treating brain 
metastases with EGFR tyrosine kinase inhibitor (TKI) alone 
without RT. Despite the known poor drug penetration of 
blood brain barrier, multiple cohort studies had reported 
encouraging response rate of brain metastases in the range 
of 50–90% with first-generation EGFR TKI alone (40-43).
Meta-analyses were published to address this important 
clinical problem. The most recent updated one (44) had 
included 15 studies with more than 1,500 subjects. The 
results suggested that radiotherapy plus EGFR TKIs gave 
superior response rate (risk ratio =1.48; 95% CI: 1.12–1.96, 
P=0.005), prolonged the time-to-CNS-progression (HR 
=0.56; 95% CI: 0.33–0.80; P<0.001) and overall survival (HR 
=0.58; 95% CI: 0.42–0.74; P<0.001) in NSCLC patients 
with BM. Combined groups, however, had higher rate of 
incidence of overall adverse effects, especially rash and dry 
skin.
Magnuson et al. has published a multi-institutional 
retrospective analysis of TKI naïve EGFR mutated lung 
cancer patients with brain metastases in 2017 (45). In this 
cohort of 351 patients, 100 received upfront SRS, 120 
received WBRT and 131 received EGFR-TKI alone. 
Multivariate analysis showed that upfront SRS vs. EGFR-
TKI, upfront WBRT vs. EGFR-TKI alone, younger age, 
better performance status, EGFR exon 19 mutation, and 
absence of extracranial metastases were associated with 
improved overall survival.
Current evidence, though mainly consists of retrospective 
studies, supports the early use of RT together with EGFR 
TKI to achieve maximal intracranial disease control. 
Evidence from randomized studies is eagerly awaited for 
this particular condition prevalent in Asian countries. 
Multiple RCTs are in progress in China (ClinicalTrials.
gov NCT01724801, NCY02714010, NCT01887795) and 
hopefully definitive results will be available soon.
Table 1 Randomized controlled trials of post-operative SRS to surgical cavity
Trials Interventions Main results
N107C/CEC.3 (30) SRS to surgical cavity and unresected met No difference in OS. Long term surgical cavity control better in WBRT 
arm. At 6 months, cognitive decline and QoL were worse in WBRT arm
Post-op WBRT and SRS to unresected met
Mahajan et al. (31) SRS to surgical cavity and unresected met SRS improved surgical cavity local control (83% vs. 57% at 6 months, 
HR 0.4). Pre-op tumor >3 cm associated with worse local control (HR 
2.4)
Observation to surgical cavity and SRS to 
unresected met
JCOG-0504 (32) Salvage SRS to residual or recurrent disease 
at surgical cavity
OS similar. Intracranial progression-free-survival longer in WBRT arm 
(10.4 vs. 4.0 months). Non-worsening MMSE and performance scale 
similar in both arms at 12 months
Post-op WBRT
QoL, quality of life; MMSE, mini-mental state examination; OS, overall survival; SRS, stereotactic radiosurgery; WBRT, whole brain 
radiation therapy.
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Summary
The encouraging results of clinical trials had established the 
important role of RT in the management of brain metastases. 
The aim of treatment has evolved from maximizing tumor 
control to neurocognitive function preservation. In future, 
multidisciplinary approach to brain metastases with surgery, 
RT and systemic therapies will further improve the outcome 
of patients.
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